Ohio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments

Ohio is third state to fund Pear’s dig­i­tal ther­a­peu­tics to tack­le addic­tion (phar­mafo­rum):

The com­pa­ny has been push­ing for more reim­burse­ment of its three mar­ket­ed DTx prod­ucts in the US fol­low­ing a first FDA approval in 2017.

Pear said that the Ohio Depart­ment of Men­tal Health and Addic­tion Ser­vices (OhioMHAS) and Recov­ery­Ohio are pro­vid­ing access to Pear’s FDA-approved DTx reSET and reSET‑O, for treat­ment of sub­stance use dis­or­der and opi­oid use dis­or­ders, respectively.

Fund­ing is pro­vid­ed by the State Opi­oid Response (SOR) 2.0 grant, admin­is­tered by OhioMHAS, and part of the US Depart­ment of Health and Human Ser­vices’ Sub­stance Abuse and Men­tal Health Ser­vices Admin­is­tra­tion (SAMHSA) SOR grant pro­gramme for peo­ple in need of pre­ven­tion, treat­ment and recov­ery sup­port for opi­oid use disorder.

The Announcement:

Pear Announces Ohio Depart­ment of Men­tal Health and Addic­tion Ser­vices will Pro­vide Access to Pre­scrip­tion Dig­i­tal Ther­a­peu­tics to Help Local Com­mu­ni­ties Con­tin­ue Fight Against Opi­oid Addic­tion (press release):

Pear Ther­a­peu­tics, Inc. announced today that the Ohio Depart­ment of Men­tal Health and Addic­tion Ser­vices (OhioMHAS) and Recov­ery­Ohio are pro­vid­ing access to Pear’s FDA-autho­rized pre­scrip­tion dig­i­tal ther­a­peu­tics (PDTs) reSET® and reSET‑O® for the treat­ment of sub­stance use dis­or­der (SUD) and opi­oid use dis­or­der (OUD), respec­tive­ly. Eli­gi­ble patients will be pre­scribed and treat­ed with reSET or reSET‑O to help com­mu­ni­ties through­out Ohio con­tin­ue the fight against addic­tion … Pear was award­ed a grant to pro­vide reSET and reSET‑O under the ‘Use of Inno­va­tion’ pro­gram that sup­ports tech­nol­o­gy and inno­va­tion advance­ments in Ohio’s behav­ioral health care deliv­ery sys­tem to sup­port Ohioans on their recov­ery jour­neys. Ohio marks the third SOR grant award­ed to Pear in 2021, with oth­er SOR grants award­ed by Indi­ana and Kentucky.…

“While the pan­dem­ic has right­ful­ly been front and cen­ter in everyone’s minds, the opi­oid epi­dem­ic hasn’t gone away – it per­sists as a threat to our cit­i­zens and our com­mu­ni­ties,” said OhioMHAS Direc­tor Lori Criss. “This fund­ing will help part­ners like Pear Ther­a­peu­tics con­nect even more Ohioans to treat­ment and recov­ery ser­vices and sup­port their use of new tech­nol­o­gy and inno­va­tion to stem the tide of addiction.”

reSET and reSET‑O have been test­ed in real-world use and ran­dom­ized con­trolled tri­als, with results pub­lished in peer-reviewed med­ical jour­nals. Both prod­ucts, which are adjunc­tive to out­pa­tient coun­selling, pro­vide patients with algo­rithm-dri­ven cog­ni­tive behav­ioral ther­a­py, flu­en­cy train­ing, and con­tin­gency man­age­ment, while clin­i­cians receive access to clin­i­cal dash­boards to inform in-office and tele vis­its. reSET is used as a monother­a­py for patients 18 years of age or old­er with sub­stance use dis­or­der and reSET‑O is used in com­bi­na­tion with trans­mu­cos­al buprenor­phine for patients 18 years of age or old­er with opi­oid use disorder.

News in Context:

• From dig­i­tal ther­a­peu­tics to per­son­al­ized men­tal health solu­tions: Pear Ther­a­peu­tics expands plat­form via part­ner­ships with Empat­i­ca, etec­tRx, Key­Wise, and Winterlight
• Pear Ther­a­peu­tics rais­es $80M; finds cost sav­ings of $2,150 per patient with opi­oid use disorder
• The FDA clears Som­ryst, Pear’s dig­i­tal ther­a­peu­tic to treat chron­ic insomnia